CVRX Strangle Strategy
CVRX (CVRx, Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
CVRX (CVRx, Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $155.5M, a beta of 0.77 versus the broader market, a 52-week range of 4.37-11.3, average daily share volume of 310K, a public-listing history dating back to 2021, approximately 206 full-time employees. These structural characteristics shape how CVRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.77 places CVRX roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on CVRX?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CVRX snapshot
As of June 29, 2026, spot at $6.00, ATM IV 154.30%, IV rank 27.33%, expected move 44.24%. The strangle on CVRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on CVRX specifically: CVRX IV at 154.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a CVRX strangle, with a market-implied 1-standard-deviation move of approximately 44.24% (roughly $2.65 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CVRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on CVRX should anchor to the underlying notional of $6.00 per share and to the trader's directional view on CVRX stock.
CVRX strangle setup
The CVRX strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CVRX near $6.00, the first option leg uses a $6.30 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CVRX chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CVRX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.30 | N/A |
| Buy 1 | Put | $5.70 | N/A |
CVRX strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CVRX strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CVRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CVRX
Strangles on CVRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CVRX chain.
CVRX thesis for this strangle
The market-implied 1-standard-deviation range for CVRX extends from approximately $3.35 on the downside to $8.65 on the upside. A CVRX long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CVRX IV rank near 27.33% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CVRX at 154.30%. As a Healthcare name, CVRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CVRX-specific events.
CVRX strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CVRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CVRX alongside the broader basket even when CVRX-specific fundamentals are unchanged. Always rebuild the position from current CVRX chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CVRX?
- A strangle on CVRX is the strangle strategy applied to CVRX (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CVRX stock trading near $6.00, the strikes shown on this page are snapped to the nearest listed CVRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CVRX strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CVRX strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 154.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CVRX strangle?
- The breakeven for the CVRX strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CVRX market-implied 1-standard-deviation expected move is approximately 44.24%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CVRX?
- Strangles on CVRX are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CVRX chain.
- How does current CVRX implied volatility affect this strangle?
- CVRX ATM IV is at 154.30% with IV rank near 27.33%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.